Get the Stockscreener App
2.77
4.48%
-0.13
Aytu Biopharma Inc stock is traded at $2.77, with a volume of 283.28K.
It is down -4.48% in the last 24 hours and up +24.77% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.90
Open:
$2.99
24h Volume:
283.28K
Relative Volume:
2.40
Market Cap:
$27.92M
Revenue:
$66.38M
Net Income/Loss:
$-14.18M
P/E Ratio:
-0.9867
EPS:
-2.8074
Net Cash Flow:
$-5.17M
1W Performance:
+8.63%
1M Performance:
+24.77%
6M Performance:
+16.14%
1Y Performance:
+48.53%
1-Day Range:
$2.651
$2.99
1-Week Range:
$2.51
$3.065
52-Week Range:
$0.95
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.74 | 29.55M | 66.38M | -14.18M | -5.17M | -2.8074 |
|
ZTS
Zoetis Inc
|
129.42 | 57.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.79 | 49.57B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.26 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.07 | 35.57B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
503.43 | 21.08B | 3.08B | 1.24B | 1.07B | 25.61 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
How Aytu BioPharma Inc. (AY20) stock reacts to fiscal policies2026 world cup usa national team group stage star players pressing system group prediction insights - Улправда
Aytu BioPharma (AYTU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Published on: 2025-12-24 03:59:28 - moha.gov.vn
Can Aytu BioPharma Inc. stock sustain revenue growthJuly 2025 Outlook & Capital Efficiency Focused Strategies - Улправда
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
Is Aytu BioPharma Inc. stock attractive for income investors2025 Winners & Losers & Low Risk High Win Rate Picks - Улправда
Aytu BioPharma announces commercial availability of EXXUA tablets - MSN
Will Aytu BioPharma Inc. stock deliver shareholder valueTrade Performance Summary & Low Drawdown Trading Strategies - DonanımHaber
Why Aytu BioPharma Inc. stock is favored by top institutionsLayoff News & Stepwise Trade Execution Plans - DonanımHaber
Why Aytu BioPharma Inc. stock attracts high net worth investorsJuly 2025 Sentiment & Precise Swing Trade Alerts - DonanımHaber
How sustainable is Aytu BioPharma Inc. stock dividend payoutEarnings Growth Summary & Safe Capital Allocation Plans - DonanımHaber
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City - ACCESS Newswire
Depression drug EXXUA takes center stage at New York investor event - Stock Titan
Aytu BioPharma launches depression drug EXXUA in U.S. market - Investing.com India
Aytu BioPharma launches depression drug EXXUA in U.S. market By Investing.com - Investing.com Nigeria
Aytu BioPharma stock rises after commercial launch of depression drug EXXUA - Investing.com Canada
Aytu BioPharma (AYTU) Launches EXXUA for Major Depressive Disorder in U.S. - GuruFocus
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults - Times Argus
Aytu BioPharma (Nasdaq: AYTU) makes EXXUA depression drug commercially available in US - Stock Titan
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome - ACCESS Newswire
AWM Investment Company Inc. Takes $1.35 Million Position in Aytu BioPharma Inc. $AYTU - Defense World
Aytu BioPharma (NASDAQ:AYTU) Given New $13.00 Price Target at Ascendiant Capital Markets - Defense World
Aytu BioScience Stockholders Approve Key Proposals - TipRanks
AYTU FinancialsIncome Statement - Quiver Quantitative
Ascendiant Capital Maintains Aytu BioPharma (AYTU) Buy Recommendation - Nasdaq
Ascendiant Capital raises Aytu Biosciences stock price target on Q1 beat - Investing.com Canada
AYTU Analyst Rating Update: Ascendiant Capital Raises Price Targ - GuruFocus
Revenue per share of Aytu BioPharma, Inc. – LSX:A3D38R - TradingView — Track All Markets
Will Aytu BioPharma Inc stock outperform Nasdaq index2025 Price Targets & Risk Controlled Daily Trade Plans - BỘ NỘI VỤ
How Low Can Aytu BioPharma Stock Really Go? - Trefis
Will Aytu BioPharma Inc. (AY20) stock profit from AI boom2025 Analyst Calls & Safe Entry Point Alerts - Newser
Will Aytu BioPharma Inc. (AY20) stock profit from fiscal stimulusJuly 2025 Patterns & Stock Portfolio Risk Management - Newser
How Aytu BioPharma Inc. (AY20) stock moves in volatile trading sessionsMarket Risk Report & Verified Technical Trade Signals - Newser
Is Aytu BioPharma Inc. (AY20) stock a fit for income portfoliosJuly 2025 Sector Moves & Fast Entry and Exit Trade Plans - Newser
Is Aytu BioPharma Inc. (AY20) stock resilient in recession scenariosJuly 2025 Catalysts & Growth Focused Entry Point Reports - Newser
Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research - Defense World
Aytu BioPharma outlines $10M EXXUA launch investment and targets breakeven at $17.3M quarterly revenue as ADHD franchise holds strong - MSN
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference - ACCESS Newswire
Aytu BioPharma (NASDAQ: AYTU) to Showcase at NobleCon21, Dec. 3 Presentation Webcast - Stock Titan
Aytu BioPharma Inc AY20 Stock Analysis and ForecastFundamental Strength Indicators & Superior Trading Strategies - earlytimes.in
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates - MSN
Positive Signs As Multiple Insiders Buy Aytu BioPharma Stock - Yahoo Finance
Published on: 2025-11-21 03:45:24 - newser.com
Why Aytu BioPharma Inc. (AY20) stock is trending on social mediaOil Prices & Real-Time Stock Entry Alerts - newser.com
Published on: 2025-11-20 04:27:18 - newser.com
Is Aytu BioPharma Inc. stock cheap at current valuationJuly 2025 Selloffs & AI Driven Price Predictions - newser.com
What risks investors should watch in Aytu BioPharma Inc. stockPortfolio Risk Summary & Reliable Entry Point Trade Alerts - newser.com
Pre Market Movers: NUTX, AYTU, NOTV Swing Big - RTTNews
What MACD signals say about Aytu BioPharma Inc.July 2025 Update & Low Drawdown Trading Techniques - newser.com
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aytu Biopharma Inc Stock (AYTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Disbrow Joshua R. | Chief Executive Officer |
Jun 09 '25 |
Buy |
1.50 |
66,666 |
99,999 |
153,257 |
| Disbrow Joshua R. | Chief Executive Officer |
Feb 28 '25 |
Buy |
1.30 |
15,000 |
19,500 |
86,591 |
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):